Member Info for VikR

Got ridiculed of this board a few weeks ago but kept calm, composed and collected to await this day. All the negative posters that debated with me and ridiculed me I said back then the RNS will do the talking and not me. Even now I hope you can repent and learn the error of your ways. Great British science paves the way on the international platform.

This alongside

FAB fusion antibodies

SVNS

APTA

All part of my strategic evidence based holdings

Good luck to all who kept the faith I don’t think there was that many towards the latter end

For those investing here you cannot expect an RNS every other week, this is not a stock to hold for a few days and then move on. Some patience is needed for the re rate but in return you will see +double figures in short order. We all know deals are being constructed in the background to out license the assets. This is unequivocally going to re rate so hard no one is going to have time to get back in when it surges to unprecedented highs.

My scientific, technical and financial opinion is this is one of the strongest holds in Pharma asset space now

Anyone selling now is risking the big upsurge with so many pieces of news imminent. For day traders or those not familiar with the backstory may risk it. I for one cannot risk any of my multimillion shares until I get that NCI validation. After that very tempted to take some profits before it hits £1+ although anyone who sees 6 figure profits sooner must get tempted to withdraw some profits. Nice situation to be in when it happens

Fab investors remain vested and steadfast💪

Someone had kindly reminded me on the telegram group of this ongoing project which commenced 4 months ago. They are collaborating with UCB on this project and best of all it’s fully funded. They will be chucking optimal all over it to get valuable case study data for themselves during the process and ultimately bring a successful in-vivo antibody which is stable and can bind to destroy cancer cells successfully. As it is a major project, updates will probably come in key milestones ending with penultimate robust full humanisation to conclude it. Whilst they have not formally agreed % splits of ownership for the new DR5 I think no one complain of a stake of potential £500 million plus+ for starters.

In all the hype of Optimal these sideline projects can get overlooked but another reason which continues to make FAB a FAB investment case

Scientists on this board will now the sheer importance of DR5 studies they have happened historically thus far

https://investorhub.fusionantibodies.com/announcements/6925611

The speculative ‘what if’ scenarios relate to the actual AI tech they are actually developing and not just hype. A lot of AI hype is based on hypothetical situations being geared to implementation and then selling the dream to prospective investors. The difference with CPAI is they are bringing tangible commodities into fruition. Albeit it may not be revenue generating yet but give the guys a chance, it’s being turned around as fast as they can.

Regarding the price that’s my personal forecast and not speculation but more of an evidence based prediction.

This time in 12 months this will be in double figures

Hi

Has James sent some communication via email to confirm upcoming news flow. Agreed there is a multitude of positive news anticipated to follow this SP. One can only excitedly imagine how fast and what level it climbs upto. Given the historical movement it is going to be rapid & steep unilaterally on the charts

Just joined the T - group looks a good base to acquire some useful information. SP is in a stable period now but won’t be long before it sharply rises to test prior higher high’s with a multitude of positive news to drop this quarter. Meanwhile very intrigued to know which pharma is offering the most money to take these projects on, there must be serious bidding war happening right now. Imagine being in a position where you name your price and dictate the terms of the deal.

Confident buy- hold - save more funds- buy again at these once in a lifetime levels. Good luck fellow holders

In the short space of time we have had a multitude of updates ahead of schedule. The professor is here to make serious revenues and before long the SP is going through to the pennies and then double figures to follow. I am amazed at the speed at which they are progressing and that in itself needs to be acknowledged and commended. This is one of the best AI shares one can put there money now and not based on speculative what if scenarios, onwards and upwards

Remain vested astute investors

The primary motivation for Dr Kinkaid joining fusion in the summer of 2022 was for optimal. He makes no mistake in hiding his passion for joining FAB purely for this reason.

Day 1 faith from our CEO in optimal 3 years to this month. He deserves to be at the realm leading us to victory

Dr Kinkaid usual calm and composed approach is welcomed and he has released some good news snippets this week to the market. Nice to see they are remaining multidisciplinary in their approach and still pumping other parts of the business supernumerary to the main optimal.

Stay vested astute investors we are another week closer to validation

Just had an email from company secretary, accepted my condolences on the recent untimely demise of Mr Kelly, may he rest in peace

He also mentioned Gaz Bisht is progressing business in an orderly manner and communicating with the necessary counterparts to progress all parts as diligently as possible

All that is needed now is patience- more topping up- and then further patience

Remain vested astute investors

Done… may I suggest all big LTHs action this request to protect your shares from the greed of the unscrupulous MM’s and put in a pending sell order for £1+ plus.

This teaser RNS from Mr Kinkaid is to let the market now we have big pharma already signed up and ready so when optimal is validated the buyers are there ready to agree a deal in whichever format that may be through licensing or outright acquisition.

Do you need any more confirmation and affirmations

As mentioned yesterday expect regular news flow now, they don’t have back to back investor presentations now lined up without concrete information to share

Phenomenal buy and hold of 2025

Great to see the above update today by the Nordic regulatory authorities. Norway has the best rates of early cancer detection in the world so they always make the best evidence based decisions for there population.

With ketamine proving its place in the treatment pathways this bodes well for a licensed approved formulation from SVNS. At the moment anyone prescribing it in Norway will be ‘off label’ so not approved or licensed and therefore at the discretion of the prescriber

This is a great clinical affirmation for SVNS’s trajectory. Still an amazing buy at this level

The team have had multiple 1:1 meetings to discuss the interesting veterinary sector antibody requirements. With this now concluded the team have attended lots of conferences this year to drum up business. This keeps ticking in the background whilst Optimal is now nearing completion.

What an exciting pivotal time to be in FAB.

Mr Kinkaid has made it clear this is only one small facet of there multidisciplinary tech offerings. The real revenues are yet to be realised and some more heavy contract wins are imminent

Top up and mop up those £££’s

This needs to blast through 1p now, huge disconnect between in situ assets and current SP. Narrow window for a top up and make a sizeable return over the next few weeks

The BoD are now ready to unleash to the world optimal and all of FABs other offerings. Having been quiet on the engagement front for a period they are now picking up the pace and arranging back to back presentations. Makes sense when you have so much to share, anyone would want to shout it from the rooftops

More affirmations for what’s incoming before the year end.

Time to top up in the consolidation phase, this is going to be huge

Cup and handle looks a good technical play here. Have just topped again this morning before the BK weekend. Solid buy here for the short/medium term

I had brought in here at the beginning of the year when it had shot up past the 1p, hoping to see a few pence in the short term. Hopefully some major DoseMeRx partnership sends this flying